From polypharmacology to target specificity: The case of PARP inhibitors

Current Topics in Medicinal Chemistry

Volumn 13, Issue 23, 2013, Pages 2939-2954

  Liscio, Paride ^a   Camaioni, Emidio ^b   Carotti, Andrea ^b   Pellicciari, Roberto ^a,b   Macchiarulo, Antonio ^b  

^a TES Pharma Srl   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cancer; Drug design; Poly(ADP ribose)polymerases; Polypharmacology; Promiscuity; Selective inhibitors; Selectivity

Indexed keywords

CORDYCEPIN; DEMECLOCYCLINE; DOXYCYCLINE; IMIDAZOQUINOLINONE; INIPARIB; ISOQUINOLINDIONE; KU 58684; KU 58948; MINOCYCLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 9; NIRAPARIB; OLAPARIB; QUINAZOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; RUCAPARIB; STAT3 PROTEIN; UNCLASSIFIED DRUG; VELIPARIB;

ARTICLE; BINDING SITE; CEREBROVASCULAR ACCIDENT; CRYSTALLOGRAPHY; DIABETES MELLITUS; DNA DAMAGE; DRUG BINDING; ENZYME SPECIFICITY; HEART MUSCLE ISCHEMIA; HUMAN; IC 50; INFLAMMATION; NEOPLASM; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRINCIPAL COMPONENT ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; POLY(ADP-RIBOSE) POLYMERASES; POLYPHARMACOLOGY; SUBSTRATE SPECIFICITY;

EID: 84889058042     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660209     Document Type: Article

References (118)

1. Chambon, P.; Weill, J. D.; Mandel, P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun., 1963, 11, 39-43.
2. Fujimura, S.; Hasegawa, S.; Shimizu, Y.; Sugimura, T. Polymerization of the adenosine 5'-diphosphate-ribose moiety of nicotinamide-adenine dinucleotide by nuclear enzyme. I. Enzymatic reactions. Biochim. Biophys. Acta, 1967, 145(2), 247-259.
3. Nishizuka, Y.; Ueda, K.; Nakazawa, K.; Hayaishi, O. Studies on the polymer of adenosine diphosphate ribose. I. Enzymic formation from nicotinamide adenine dinuclotide in mammalian nuclei. J. Biol. Chem., 1967, 242(13), 3164-3171.
4. Hottiger, M. O.; Hassa, P. O.; Lüscher, B.; Schüler, H.; Koch-Nolte, F. Toward a unified nomenclature for mammalian ADPribosyltransferases. Trends Biochem. Sci., 2010, 35(4), 208-219.
5. Hassa, P. O.; Hottiger, M. O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADPribose polymerases. Front. Biosci., 2008, 13, 3046-3082.
6. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADPribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol., 2006, 7(7), 517-528.
7. Rouleau, M.; Patel, A.; Hendzel, M. J.; Kaufmann, S. H.; Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer, 2010, 10(4), 293-301.
8. Jeggo, P. A. DNA repair: PARP-another guardian angel? Curr. Biol., 1998, 8(2), 49-51.
9. Luo, X.; Kraus, W. L. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev., 2012, 26(5), 417-432.
10. Ji, Y.; Tulin, A. V. The roles of PARP1 in gene control and cell differentiation. Curr. Opin. Genet. Dev., 2010, 20(5), 512-518.
11. Kraus, W. L. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr. Opin. Cell Biol., 2008, 20(3), 294-302.
12. Alvarez-Gonzalez, R. Genomic maintenance: the p53 poly(ADPribosyl) ation connection. Sci. STKE, 2007, 2007(415), pe68.
13. Bai, P.; Canto, C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab., 2012, 16(3), 290-295.
14. Gibson, B. A.; Kraus, W. L. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol., 2012, 13(7), 411-424.
15. Horvath, E. M.; Szabo, C. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update. Drug News Perspect., 2007, 20(3), 171-181.
16. de la Lastra, C. A.; Villegas, I.; Sanchez-Fidalgo, S. Poly(ADPribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr. Pharm. Des., 2007, 13(9), 933-962.
17. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 2005, 434(7035), 913-917.
18. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434(7035), 917-921.
19. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H.; de Bono, J. S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med., 2009, 361(2), 123-134.
20. Basu, B.; Yap, T. A.; Molife, L. R.; de Bono, J. S. Targeting the DNA damage response in oncology: past, present and future perspectives. Curr. Opin. Oncol. 2012, 24(3), 316-324.
21. Moroni, F. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage. Curr. Opin. Pharmacol., 2008, 8(1), 96-103.
22. Eliasson, M. J.; Sampei, K.; Mandir, A. S.; Hurn, P. D.; Traystman, R. J.; Bao, J.; Pieper, A.; Wang, Z. Q.; Dawson, T. M.; Snyder, S. H.; Dawson, V. L. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med., 1997, 3(10), 1089-1095.
23. Chiarugi, A. Poly(ADP-ribosyl)ation and stroke. Pharmacol. Res. 2005, 52(1), 15-24.
24. Chiarugi, A. Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol. Sci., 2002, 23(3), 122-129.
25. Underhill, C.; Toulmonde, M.; Bonnefoi, H. A review of PARP inhibitors: from bench to bedside. Ann. Oncol., 2011, 22(2), 268-279.
26. Telli, M. L. PARP inhibitors in cancer: moving beyond BRCA. Lancet Oncol., 2011, 12(9), 827-828.
27. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J. Med. Chem., 2010, 53(12), 4561-4584.
28. Davar, D.; Beumer, J. H.; Hamieh, L.; Tawbi, H. Role of PARP inhibitors in cancer biology and therapy. Curr. Med. Chem., 2012, 19(23), 3907-3921.
29. Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S. M.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R. K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 2010, 376(9737), 235-244.
30. Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R. K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 2010, 376(9737), 245-251.
31. Guha, M. PARP inhibitors stumble in breast cancer. Nat. Biotechnol., 2011, 29(5), 373-374.
32. Tulin, A. Re-evaluating PARP1 inhibitor in cancer. Nat. Biotechnol., 2011, 29(12), 1078-1079.
33. Balmana, J.; Domchek, S. M.; Tutt, A.; Garber, J. E. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov., 2011, 1(1), 29-34.
34. Merino, A.; Bronowska, A. K.; Jackson, D. B.; Cahill, D. J. Drug profiling: knowing where it hits. Drug Discov. Today, 2010, 15(17-18), 749-756.
35. Metz, J. T.; Hajduk, P. J. Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. Curr. Opin. Chem. Biol., 2010, 14(4), 498-504.
36. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs. Nature, 2009, 462(7270), 175-181.
37. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 2007, 25(2), 197-206.
38. Paolini, G. V.; Shapland, R. H.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol., 2006, 24(7), 805-815.
39. Gleeson, M. P.; Hersey, A.; Montanari, D.; Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov., 2011, 10(3), 197-208.
40. Mestres, J.; Gregori-Puigjane, E.; Valverde, S.; Sole, R. V. Data completeness-the Achilles heel of drug-target networks. Nat. Biotechnol., 2008, 26(9), 983-984.
41. Boran, A. D.; Iyengar, R. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel., 2010, 13(3), 297-309.
42. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol., 2006, 16(1), 127-136.
43. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today, 2007, 12(3-4), 156-160.
44. Azzaoui, K.; Hamon, J.; Faller, B.; Whitebread, S.; Jacoby, E.; Bender, A.; Jenkins, J. L.; Urban, L. Modeling promiscuity based on in vitro safety pharmacology profiling data. Chem. Med. Chem., 2007, 2(6), 874-880.
45. Stockwell, G. R.; Thornton, J. M. Conformational diversity of ligands bound to proteins. J. Mol. Biol., 2006, 356(4), 928-944.
46. Perola, E.; Charifson, P. S. Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding. J. Med. Chem., 2004, 47(10), 2499-2510.
47. Clemons, P. A.; Wilson, J. A.; Dancik, V.; Muller, S.; Carrinski, H. A.; Wagner, B. K.; Koehler, A. N.; Schreiber, S. L. Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. Proc. Natl. Acad. Sci. USA, 2011, 108(17), 6817-6822.
48. Sturm, N.; Desaphy, J.; Quinn, R. J.; Rognan, D.; Kellenberger, E. Structural insights into the molecular basis of the ligand promiscuity. J. Chem. Inf. Model., 2012, 52(9), 2410-2421.
49. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov., 2007, 6(11), 881-890.
50. Nobeli, I.; Favia, A. D.; Thornton, J. M. Protein promiscuity and its implications for biotechnology. Nat. Biotechnol., 2009, 27(2), 157-167.
51. Redinbo, M. R. Promiscuity: what protects us, perplexes us. Drug Discov. Today, 2004, 9(10), 431-432.
52. Tokuriki, N.; Tawfik, D. S. Protein dynamism and evolvability. Science, 2009, 324(5924), 203-207.
53. Babtie, A.; Tokuriki, N.; Hollfelder, F. What makes an enzyme promiscuous? Curr. Opin. Chem. Biol., 2010, 14(2), 200-207.
54. Hettne, K.; Cases, M.; Boyer, S.; Mestres, J. Connecting small molecules to nuclear receptor pathways. Curr. Top. Med. Chem., 2007, 7(15), 1530-1536.
55. Wahlberg, E.; Karlberg, T.; Kouznetsova, E.; Markova, N.; Macchiarulo, A.; Thorsell, A. G.; Pol, E.; Frostell, Å.; Ekblad, T.; Öncü, D.; Kull, B.; Robertson, G. M.; Pellicciari, R.; Schüler, H.; Weigelt, J. Family wide chemical profiling and structural analysis of PARP and Tankyrase inhibitors. Nature Biotechnol., 2012, 30(3), 283-288.
56. Abdelkarim, G. E.; Gertz, K.; Harms, C.; Katchanov, J.; Dirnagl, U.; Szabo, C.; Endres, M. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int. J. Mol. Med. 2001, 7(3), 255-260.
57. Garcia Soriano, F.; Virag, L.; Jagtap, P.; Szabo, E.; Mabley, J. G.; Liaudet, L.; Marton, A.; Hoyt, D. G.; Murthy, K. G.; Salzman, A. L.; Southan, G. J.; Szabo, C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med., 2001, 7(1), 108-113.
58. English, F. A.; McCarthy, F. P.; Andersson, I. J.; Stanley, J. L.; Davidge, S. T.; Baker, P. N.; Walsh, S. K.; Kenny, L. C. Administration of the PARP inhibitor Pj34 ameliorates the impaired vascular function associated with eNOS(-/-) mice. Reprod. Sci., 2012, 19(8), 806-813.
59. Faro, R.; Toyoda, Y.; McCully, J. D.; Jagtap, P.; Szabo, E.; Virag, L.; Bianchi, C.; Levitsky, S.; Szabo, C.; Sellke, F. W. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann. Thorac. Surg., 2002, 73(2), 575-781.
60. Yam-Canul, P.; Chirino, Y. I.; Sanchez-Gonzalez, D. J.; Martinez-Martinez, C. M.; Cruz, C.; Pedraza-Chaverri, J. PJ34, a poly adenosine diphosphate-ribose polymerase inhibitor, attenuates chromate-induced nephrotoxicity. Basic Clin. Pharmacol. Toxicol., 2008, 102(5), 483-488.
61. Tu, Z.; Chu, W.; Zhang, J.; Dence, C. S.; Welch, M. J.; Mach, R. H. Synthesis and in vivo evaluation of [11C]PJ34, a potential radiotracer for imaging the role of PARP-1 in necrosis. Nucl. Med. Biol., 2005, 32(5), 437-443.
62. Mehrotra, P.; Hollenbeck, A.; Riley, J. P.; Li, F.; Patel, R. J.; Akhtar, N.; Goenka, S. Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease. J. Allergy Clin. Immunol., 2013, 131(2), 521-531.
63. Di Paola, S.; Micaroni, M.; Di Tullio, G.; Buccione, R.; Di Girolamo, M. PARP16/ARTD15 is a novel endoplasmic-reticulumassociated mono-ADP-ribosyltransferase that interacts with, and modifies karyopherin-ss1. PLoS One, 2012, 7(6), e37352.
64. Nicolescu, A. C.; Holt, A.; Kandasamy, A. D.; Pacher, P.; Schulz, R. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem. Biophys. Res. Commun., 2009, 387(4), 646-650.
65. Madison, D. L.; Stauffer, D.; Lundblad, J. R. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. DNA Repair, 2011, 10(10), 1003-1013.
66. Castiel, A.; Visochek, L.; Mittelman, L.; Dantzer, F.; Izraeli, S.; Cohen-Armon, M. A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells. BMC Cancer, 2011, 11, 412.
67. Antolin, A. A.; Jalencas, X.; Yelamos, J.; Mestres, J. Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem. Biol., 2012, 7(12), 1962-1967.
68. Nasrabady, S. E.; Kuzhandaivel, A.; Akrami, A.; Bianchetti, E.; Milanese, M.; Bonanno, G.; Nistri, A. Unusual increase in lumbar network excitability of the rat spinal cord evoked by the PARP-1 inhibitor PJ-34 through inhibition of glutamate uptake. Neuropharmacology, 2012, 63(3), 415-426.
69. Chuang, H. C.; Kapuriya, N.; Kulp, S. K.; Chen, C. S.; Shapiro, C. L. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res. Treat., 2012, 134(2), 649-659.
70. Sallmann, F. R.; Vodenicharov, M. D.; Wang, Z. Q.; Poirier, G. G. Characterization of sPARP-1. An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks. J. Biol. Chem., 2000, 275(20), 15504-15511.
71. Citarelli, M.; Teotia, S.; Lamb, R. S. Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes. BMC Evol. Biol., 2010, 10, 308.
72. Aguiar, R. C.; Takeyama, K.; He, C.; Kreinbrink, K.; Shipp, M. A. B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J. Biol. Chem., 2005, 280(40), 33756-33765.
73. Bamborough, P.; Drewry, D.; Harper, G.; Smith, G. K.; Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem., 2008, 51(24), 7898-7914.
74. Buki, K. G.; Bauer, P. I.; Mendeleyev, J.; Hakam, A.; Kun, E. Destabilization of Zn2+ coordination in ADP-ribose transferase (polymerizing) by 6-nitroso-1, 2-benzopyrone coincidental with inactivation of the polymerase but not the DNA binding function. FEBS Lett., 1991, 290(1-2), 181-185.
75. Tseng, A., Jr.; Lee, W. M.; Jakobovits, E. B.; Kirsten, E.; Hakam, A.; McLick, J.; Buki, K.; Kun, E. Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly(ADP ribose) polymerase. Proc. Natl. Acad. Sci. USA, 1987, 84(4), 1107-1111.
76. Murai, J.; Huang, S. Y.; Das, B. B.; Renaud, A.; Zhang, Y.; Doroshow, J. H.; Ji, J.; Takeda, S.; Pommier, Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res., 2012, 72(21), 5588-5599.
77. Kirby, C. A.; Cheung, A.; Fazal, A.; Shultz, M. D.; Stams, T. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 2012, 68(Pt2), 115-118.
78. Lehtio, L.; Jemth, A. S.; Collins, R.; Loseva, O.; Johansson, A.; Markova, N.; Hammarstrom, M.; Flores, A.; Holmberg-Schiavone, L.; Weigelt, J.; Helleday, T.; Schuler, H.; Karlberg, T. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem., 2009, 52(9), 3108-3111.
79. Chen, B.; Dodge, M. E.; Tang, W.; Lu, J.; Ma, Z.; Fan, C. W.; Wei, S.; Hao, W.; Kilgore, J.; Williams, N. S.; Roth, M. G.; Amatruda, J. F.; Chen, C.; Lum, L. Small molecule-mediated disruption of Wntdependent signaling in tissue regeneration and cancer. Nat. Chem. Biol., 2009, 5(2), 100-107.
80. Huang, S. M.; Mishina, Y. M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G. A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S.; Hild, M.; Shi, X.; Wilson, C. J.; Mickanin, C.; Myer, V.; Fazal, A.; Tomlinson, R.; Serluca, F.; Shao, W.; Cheng, H.; Shultz, M.; Rau, C.; Schirle, M.; Schlegl, J.; Ghidelli, S.; Fawell, S.; Lu, C.; Curtis, D.; Kirschner, M. W.; Lengauer, C.; Finan, P. M.; Tallarico, J. A.; Bouwmeester, T.; Porter, J. A.; Bauer, A.; Cong, F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature, 2009, 461(7264), 614-620.
81. Voronkov, A.; Holsworth, D. D.; Waaler, J.; Wilson, S. R.; Ekblad, B.; Perdreau-Dahl, H.; Dinh, H.; Drewes, G.; Hopf, C.; Morth, J. P.; Krauss, S. Structural Basis and SAR for G007-LK, a Lead Stage 1, 2, 4-Triazole Based Specific Tankyrase 1/2 Inhibitor. J. Med. Chem., 2013, 56(7), 3012-3023.
82. Alano, C. C.; Kauppinen, T. M.; Valls, A. V.; Swanson, R. A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. USA, 2006, 103(25), 9685-9690.
83. Tao, R.; Kim, S. H.; Honbo, N.; Karliner, J. S.; Alano, C. C. Minocycline protects cardiac myocytes against simulated ischemiareperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J. Cardiovasc. Pharmacol., 2010, 56(6), 659-668.
84. Hess, D. C.; Fagan, S. C. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline. Pharmacotherapy, 2010, 30(7 Pt 2), 55-61S.
85. Ng, T. B.; Wang, H. X. Pharmacological actions of Cordyceps, a prized folk medicine. J. Pharm. Pharmacol., 2005, 57(12), 1509-1519.
86. Kim, H.; Naura, A. S.; Errami, Y.; Ju, J.; Boulares, A. H. Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP. Mol. Med., 2011, 17(9-10), 893-900.
87. Lee, H. J.; Burger, P.; Vogel, M.; Friese, K.; Bruning, A. The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells. Invest. New Drugs, 2012, 30(5), 1917-1925.
88. Banasik, M.; Stedeford, T.; Strosznajder, R. P. Natural inhibitors of poly(ADP-ribose) polymerase-1. Mol. Neurobiol., 2012, 46(1), 55-63.
89. Smock, R. G.; Gierasch, L. M. Sending signals dynamically. Science. 2009, 324(5924), 198-203.
90. Bellocchi, D.; Macchiarulo, A.; Costantino, G.; Pellicciari, R. Docking studies on PARP-1 inhibitors: insights into the role of a binding pocket water molecule. Bioorg. Med. Chem., 2005, 13(4), 1151-1157.
91. Pellicciari, R.; Camaioni, E.; Gilbert, A. M.; Macchiarulo, A.; Bikker, J. A.; Shah, F.; Bard, J.; Costantino, G.; Gioiello, A.; Robertson, G. M.; Sabbatini, P.; Venturoni, F.; Liscio, P.; Carotti, A.; Bellocchi, D.; Cozzi, A.; Wood, A.; Gonzales, C.; Zaleska, M. M.; Ellingboe, J. W.; Moroni, F. Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: From TIQ-A to HYDAMTIQ. Med. Chem. Commun., 2011, 2, 559-565.
92. Ishida, J.; Yamamoto, H.; Kido, Y.; Kamijo, K.; Murano, K.; Miyake, H.; Ohkubo, M.; Kinoshita, T.; Warizaya, M.; Iwashita, A.; Mihara, K.; Matsuoka, N.; Hattori, K. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorg. Med. Chem., 2006, 14(5), 1378-1390.
93. Eltze, T.; Boer, R.; Wagner, T.; Weinbrenner, S.; McDonald, M. C.; Thiemermann, C.; Burkle, A.; Klein, T. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol. Pharmacol., 2008, 74(6), 1587-1598.
94. Pellicciari, R.; Camaioni, E.; Costantino, G.; Formentini, L.; Sabbatini, P.; Venturoni, F.; Eren, G.; Bellocchi, D.; Chiarugi, A.; Moroni, F. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. ChemMedChem, 2008, 3(6), 914-923.
95. Sunderland, P. T.; Woon, E. C.; Dhami, A.; Bergin, A. B.; Mahon, M. F.; Wood, P. J.; Jones, L. A.; Tully, S. R.; Lloyd, M. D.; Thompson, A. S.; Javaid, H.; Martin, N. M.; Threadgill, M. D. 5-Benzamidoisoquinolin-1-ones and 5-(omegacarboxyalkyl) isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2). J. Med. Chem., 2011, 54(7), 2049-2059.
96. Pescatore, G.; Branca, D.; Fiore, F.; Kinzel, O.; Bufi, L. L.; Muraglia, E.; Orvieto, F.; Rowley, M.; Toniatti, C.; Torrisi, C.; Jones, P. Identification and SAR of novel pyrrolo[1, 2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett., 2010, 20(3), 1094-1099.
97. Ferrigno, F.; Branca, D.; Kinzel, O.; Lillini, S.; Llauger Bufi, L.; Monteagudo, E.; Muraglia, E.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Torrisi, C.; Jones, P. Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4, 5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells. Bioorg. Med. Chem. Lett., 2010, 20(3), 1100-1105.
98. Torrisi, C.; Bisbocci, M.; Ingenito, R.; Ontoria, J. M.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Jones, P. Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett., 2010, 20(2), 448-452.
99. Scarpelli, R.; Boueres, J. K.; Cerretani, M.; Ferrigno, F.; Ontoria, J. M.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Jones, P. Synthesis and biological evaluation of substituted 2-phenyl-2Hindazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(2), 488-492.
100. Branca, D.; Cerretani, M.; Jones, P.; Koch, U.; Orvieto, F.; Palumbi, M. C.; Rowley, M.; Toniatti, C.; Muraglia, E. Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(15), 4042-4045.
101. Orvieto, F.; Branca, D.; Giomini, C.; Jones, P.; Koch, U.; Ontoria, J. M.; Palumbi, M. C.; Rowley, M.; Toniatti, C.; Muraglia, E. Identification of substituted pyrazolo[1, 5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(15), 4196-4200.
102. Jones, P.; Altamura, S.; Boueres, J.; Ferrigno, F.; Fonsi, M.; Giomini, C.; Lamartina, S.; Monteagudo, E.; Ontoria, J. M.; Orsale, M. V.; Palumbi, M. C.; Pesci, S.; Roscilli, G.; Scarpelli, R.; Schultz-Fademrecht, C.; Toniatti, C.; Rowley, M. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors. J. Med. Chem., 2009, 52(22), 7170-7185.
103. Mueller, S.; Bhargava, S.; Molinaro, A. M.; Yang, X.; Kolkowitz, I.; Olow, A.; Wehmeijer, N.; Orbach, S.; Chen, J.; Matthay, K. K.; Haas-Kogan, D. A. Poly (ADP-Ribose) Polymerase Inhibitor MK-4827 together with Radiation as a Novel Therapy for Metastatic Neuroblastoma. Anticancer Res., 2013, 33(3), 755-762.
104. Wang, L.; Mason, K. A.; Ang, K. K.; Buchholz, T.; Valdecanas, D.; Mathur, A.; Buser-Doepner, C.; Toniatti, C.; Milas, L. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest. New Drugs, 2012, 30(6), 2113-2120.
105. Menear, K. A.; Adcock, C.; Boulter, R.; Cockcroft, X. L.; Copsey, L.; Cranston, A.; Dillon, K. J.; Drzewiecki, J.; Garman, S.; Gomez, S.; Javaid, H.; Kerrigan, F.; Knights, C.; Lau, A.; Loh, V. M., Jr.; Matthews, I. T.; Moore, S.; O'Connor, M. J.; Smith, G. C.; Martin, N. M. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem., 2008, 51(20), 6581-6591.
106. Narwal, M.; Venkannagari, H.; Lehtio, L. Structural basis of selective inhibition of human tankyrases. J. Med. Chem., 2012, 55(3), 1360-1367.
107. Donawho, C. K.; Luo, Y.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S.; Grimm, D. R.; Guan, R.; Han, E. K.; Holley-Shanks, R. R.; Hristov, B.; Idler, K. B.; Jarvis, K.; Johnson, E. F.; Kleinberg, L. R.; Klinghofer, V.; Lasko, L. M.; Liu, X.; Marsh, K. C.; McGonigal, T. P.; Meulbroek, J. A.; Olson, A. M.; Palma, J. P.; Rodriguez, L. E.; Shi, Y.; Stavropoulos, J. A.; Tsurutani, A. C.; Zhu, G. D.; Rosenberg, S. H.; Giranda, V. L.; Frost, D. J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res., 2007, 13(9), 2728-2737.
108. Penning, T. D.; Zhu, G. D.; Gandhi, V. B.; Gong, J.; Thomas, S.; Lubisch, W.; Grandel, R.; Wernet, W.; Park, C. H.; Fry, E. H.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E. F.; Donawho, C. K.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Olson, A. M.; Marsh, K. C.; Luo, Y.; Rosenberg, S. H.; Giranda, V. L. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg. Med. Chem., 2008, 16(14), 6965-6975.
109. Kinders, R. J.; Hollingshead, M.; Khin, S.; Rubinstein, L.; Tomaszewski, J. E.; Doroshow, J. H.; Parchment, R. E.; National Cancer Institute Phase 0 Clinical Trials, T. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin. Cancer Res., 2008, 14(21), 6877-6885.
110. Karlberg, T.; Markova, N.; Johansson, I.; Hammarstrom, M.; Schutz, P.; Weigelt, J.; Schuler, H. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J. Med. Chem., 2010, 53(14), 5352-5355.
111. Lehtio, L.; Collins, R.; van den Berg, S.; Johansson, A.; Dahlgren, L. G.; Hammarstrom, M.; Helleday, T.; Holmberg-Schiavone, L.; Karlberg, T.; Weigelt, J. Zinc binding catalytic domain of human tankyrase 1. J. Mol. Biol., 2008, 379(1), 136-145.
112. Waaler, J.; Machon, O.; Tumova, L.; Dinh, H.; Korinek, V.; Wilson, S. R.; Paulsen, J. E.; Pedersen, N. M.; Eide, T. J.; Machonova, O.; Gradl, D.; Voronkov, A.; von Kries, J. P.; Krauss, S. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res., 2012, 72(11), 2822-2832.
113. Shultz, M. D.; Kirby, C. A.; Stams, T.; Chin, D. N.; Blank, J.; Charlat, O.; Cheng, H.; Cheung, A.; Cong, F.; Feng, Y.; Fortin, P. D.; Hood, T.; Tyagi, V.; Xu, M.; Zhang, B.; Shao, W. [1, 2, 4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1, 2, 4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J. Med. Chem., 2012, 55(3), 1127-1136.
114. Waaler, J.; Machon, O.; von Kries, J. P.; Wilson, S. R.; Lundenes, E.; Wedlich, D.; Gradl, D.; Paulsen, J. E.; Machonova, O.; Dembinski, J. L.; Dinh, H.; Krauss, S. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res., 2011, 71(1), 197-205.
115. Lau, T.; Chan, E.; Callow, M.; Waaler, J.; Boggs, J.; Blake, R. A.; Magnuson, S.; Sambrone, A.; Schutten, M.; Firestein, R.; Machon, O.; Korinek, V.; Choo, E.; Diaz, D.; Merchant, M.; Polakis, P.; Holsworth, D. D.; Krauss, S.; Costa, M. A Novel Tankyrase Smallmolecule Inhibitor Suppresses APC Mutation-driven Colorectal Tumor Growth. Cancer Res., 2013, 73(10), 3132-3144.
116. Bregman, H.; Gunaydin, H.; Gu, Y.; Schneider, S.; Wilson, C.; DiMauro, E. F.; Huang, X. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket. J. Med. Chem., 2013, 56(3), 1341-1345.
117. Gunaydin, H.; Gu, Y.; Huang, X. Novel binding mode of a potent and selective tankyrase inhibitor. PLoS One, 2012, 7(3), e33740.
118. Frye, S. V. The art of the chemical probe. Nat. Chem. Biol., 2010, 6(3), 159-161.